The spinout, known as Celea Therapeutics, will advance what’s designed to be an improved version of the drug pirfenidone for idiopathic pulmonary fibr...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not caused by cystic fibrosis....

The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a multibillion-dollar deal that hadn’t y...

With a strong launch underway for a bladder cancer gene therapy, Ferring Pharmaceuticals is finding the kind of commercial success that’s eluded many...

A regimen involving the company’s shot failed a Phase 3 trial “by a hair,” an executive said, leading the company to believe it still could win U.S. a...

DTC isn’t converting to Rxs at the pharmacy. Learn how access may be key to your brand’s success.

One analyst speculated that, going forward, Prasad may be less “heavy-handed” in reviewing rare disease therapies given the public backlash to the age...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an acquisition of its one-ti...

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its slipping position in the lucra...

One vaccine expert called the move, which cancels some $500 million in messenger RNA research contracts, a “giant step backward for science.”